Lex

Samsung Bioepis - a spin-off sweetener?

Drugmaker Samsung Bioepis is looking to list in New York, saying it needs to fund its development of biosimilar drugs. But with a large and lucrative biotech market, why would Samsung spin off the company? Lex's Oliver Ralph asks Lucy Colback.